Avid Bioservices Inc (CDMO)

[bimerkjaere]

Sure we can speculate, but that is all it would be. If I had to speculate, I would say the placebo arm's MOS was not affected by the discrepancy. In a sense we are talking about two different impacts.

1. What impact, if any, on docetaxel's MOS be if one or two, etc.. of bavi 1mg doses were given?

2. What impact, if any, would bavi 1mg MOS be if it missed one or two, etc.. doses?

As noted, I would say adding a dose or two of bavi to docetaxel (if that is what happened) would likely not impact survival, meaning the 5.6 month reported survival is likely a valid number.

As for bavi's missed doses.. it is hard to speculate, but perhaps this had more of an impact than the situation listed above.

IMO